Photo by kalvisuals from unsplash
LoPiccolo et al. describe the very effective clinical management of severe portal hypertension associated with nodular regenerative hyperplasia (NRH) developing acutely during melanoma treatment with pembrolizumab, a novel IgG4 antibody targeting… Click to show full abstract
LoPiccolo et al. describe the very effective clinical management of severe portal hypertension associated with nodular regenerative hyperplasia (NRH) developing acutely during melanoma treatment with pembrolizumab, a novel IgG4 antibody targeting the anti-programmed death-1 receptor on lymphocytes, which physiologically serves as an immune check-point blocker(1). NRH is a rare diffuse architectural disturbance of the liver thought to be caused by uneven microperfusion secondary to endothelial damage of the small portal vein radicles(2). This article is protected by copyright. All rights reserved.
Journal Title: Hepatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!